James McNally - GenMark Diagnostics President

President

Mr. James B. McNally is Senior Vice President, Sales and Marketing of the company. Mr. McNally previously served as Senior Vice President, Marketing and Business Development from October 2016 to August 2018. Prior to joining the Company, Mr. McNally served as Vice President, Marketing and Strategy for Genalyte, Inc., a diagnostics company that is developing an immunoassay platform for near patient testing, from May 2016 to October 2016. From September 2010 to May 2016, Mr. McNally held roles of increasing responsibility with Volcano Corporation and Phillips Volcano, including most recently Director of Marketing and Systems Segment Leader. Prior to joining Volcano Corporationrationration, Mr. McNally held engineering roles with Boston Scientific and Goodrich Corporation and worked in Morgan Stanleys investment banking division since 2018.
Age 38
Tenure 6 years
Professional MarksMBA
Phone760 448-4300
Webwww.genmarkdx.com
McNally received a B.S.E. in Electrical Engineering with high honors from Princeton University, an M.S. degree in Optical Sciences from the University of Arizona, and an M.B.A. with high distinction from Harvard Business School.

GenMark Diagnostics Management Efficiency

The company has return on total asset (ROA) of (2.63) % which means that it has lost $2.63 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (35.06) %, meaning that it created substantial loss on money invested by shareholders. GenMark Diagnostics' management efficiency ratios could be used to measure how well GenMark Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 87.14 M in liabilities with Debt to Equity (D/E) ratio of 0.93, which is about average as compared to similar companies. GenMark Diagnostics has a current ratio of 3.84, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist GenMark Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, GenMark Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GenMark Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GenMark to invest in growth at high rates of return. When we think about GenMark Diagnostics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 12 records

PRESIDENT Age

James HammanArtisan Partners Asset
54
Sarah JohnsonArtisan Partners Asset
52
Ariel GorelikAmTrust Financial Services
43
Eileen KweiArtisan Partners Asset
45
Stephen UngarAmTrust Financial Services
60
Jason GottliebArtisan Partners Asset
54
Prashanth GanguSiriuspoint
40
David SaksAmTrust Financial Services
56
Dean PatenaudeArtisan Partners Asset
52
Ronald PipolyAmTrust Financial Services
56
Adam KarkowskyAmTrust Financial Services
48
Christopher LongoAmTrust Financial Services
42
GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. The company was incorporated in 2010 and is headquartered in Carlsbad, California. Genmark Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 618 people. GenMark Diagnostics (GNMK) is traded on NASDAQ Exchange in USA and employs 618 people.

Management Performance

GenMark Diagnostics Leadership Team

Elected by the shareholders, the GenMark Diagnostics' board of directors comprises two types of representatives: GenMark Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GenMark. The board's role is to monitor GenMark Diagnostics' management team and ensure that shareholders' interests are well served. GenMark Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GenMark Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
James McNally, Senior Vice President Marketing and Business Development
Michael Gleeson, Sr. VP of North American Commercial Operations
Brian Mitchell, Senior Vice President Operations
Kevin OBoyle, Independent Director
Jennifer Williams, Sr. VP of HR
Scott Mendel, CFO
Ingo Chakravarty, Sr. VP of International
James Fox, Independent Director
Jon Kayyem, Founder and Sr. VP of RandD
Eric Stier, Senior Vice President General Counsel, Secretary
Michael Kagnoff, Director
Hany Massarany, CEO and President and Director
Lisa Giles, Director
Daryl Faulkner, Independent Director
Johnny Ek, CFO

GenMark Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GenMark Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Other Consideration for investing in GenMark Stock

If you are still planning to invest in GenMark Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GenMark Diagnostics' history and understand the potential risks before investing.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Global Correlations
Find global opportunities by holding instruments from different markets